Accordingly, inhibition of MALAT1 using resveratrol was found to increase miR-129 levels, consequently downregulating SNCA expression and improving disease-related phenotypes in a PD mouse model (Xia et al., 2019). This evidence concerns the gene SNCA and Parkinson disease.